# Colossal Biosciences in Talks to Raise New Funding at $20B–$30B Valuation The de-extinction startup continues to expand its biotech innovations. - **Source:** [TechCrunch](https://techcrunch.com) - **Published:** 2026-07-20 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/dea637f2-3bbc-4d9d-8881-784e73f828a8 ## Colossal's Growth Story Colossal Biosciences reached a $10.2 billion valuation last year. Now, it is in talks to raise new funding at a $20–$30 billion valuation. This increase reflects investor confidence in the company's groundbreaking biotech innovations. ## Revenue Streams Colossal has started generating revenue over the past year. The company has three main revenue sources: conservation technologies, spin-off startups, and biodiversity credits. Deals with countries like the U.S. and UAE have strengthened its financial position. ## Spin-offs and Collaborations Colossal has launched three spin-offs: Breaking (plastic degradation), Form Bio ($30M funding), and Astromech ($2B valuation). It also partnered with the University of Tasmania to protect Tasmanian devils, expanding its biotech influence. ## De-Extinction Projects Colossal aims to revive six species, with the bluebuck antelope as its latest target. It also plans to commercialize its artificial womb technology next year, which could have applications in human fertility treatments. ## Biodiversity Credits The company plans to sell biodiversity credits by reintroducing extinct species to their habitats. These credits, similar to carbon credits, are part of Colossal's strategy to create a sustainable revenue model. ## Deep Tech Sector Trends Colossal's success highlights the rise of deep tech sectors like longevity and alternative energy. Its innovative approach could set new standards in biotechnology and conservation. ## Sources covering this story - https://techcrunch.com/2026/07/20/colossal-biosciences-reportedly-in-talks-to-raise-new-capital-at-20b-30b-valuation/ — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._